Search

Your search keyword '"Myositis -- Drug therapy"' showing total 8 results
Start Over Descriptor "Myositis -- Drug therapy" Publication Year Range Last 10 years
8 results on '"Myositis -- Drug therapy"'

1. Medical Oncology Service Researchers Provide New Study Findings on Myositis (Fatal Case of Immune-Related Myocarditis and Myositis Due to Treatment with Immune Checkpoint and Tyrosine Kinase Inhibitors)

Subjects
Tyrosine -- Reports, Myositis -- Drug therapy, Phenols -- Reports, Immunotherapy -- Reports, Axitinib -- Reports, Health
Abstract

2024 OCT 30 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Fresh data on myositis are presented in a new report. According to news reporting from [...]

Published
2024

2. Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis

Subjects
United States. Food and Drug Administration, T cells, Myositis -- Drug therapy, Orphan drugs, B cells, Banking, finance and accounting industries, Business
Abstract

PHILADELPHIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with [...]

Published
2024

3. Findings from Mayo Clinic Has Provided New Data on Myositis Ossificans [Reduction of New Heterotopic Ossification (Ho) In the Open-label, Phase 3 Move Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva (Fop)]

Subjects
Myositis -- Drug therapy, Ossification -- Drug therapy, Retinoids -- Testing -- Complications and side effects, Health
Abstract

2023 APR 8 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Musculoskeletal Diseases and Conditions - Myositis Ossificans have [...]

Published
2023

4. Investigators from Institute for Cancer Research and Treatment (IRCCS) Have Reported New Data on Myositis (Exacerbation of Murine Experimental Autoimmune Myositis by Toll-Like Receptor 7/8)

Subjects
Physical fitness, Cancer -- Drug therapy, Cancer research, Myositis -- Drug therapy, Interferon, Health
Abstract

2018 AUG 25 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Musculoskeletal Diseases and Conditions - Myositis have been [...]

Published
2018

5. Researchers at University of Puerto Rico Target Systemic Lupus Erythematosus (Efficacy of immunosuppressive treatment in a systemic lupus erythematosus patient presenting with inclusion body myositis)

Subjects
International Business Machines Corp., Lupus -- Drug therapy, Systemic lupus erythematosus -- Drug therapy, Physical fitness, Myositis -- Drug therapy, Computer industry, Microcomputer industry, Computer industry, Health, University of Puerto Rico
Abstract

2016 SEP 3 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in Lupus. According to news reporting out of [...]

Published
2016

6. Orphazyme's arimoclomol receives US Fast Track designation in sporadic Inclusion Body Myositis

Subjects
United States. Food and Drug Administration, Myositis -- Drug therapy, Shock, General interest, News, opinion and commentary
Abstract

Copenhagen: ORPHAZYME A/S has issued the following press release: Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today received Fast Track [...]

Published
2019

7. Orphazymes arimoclomol receives US Fast Track designation in sporadic Inclusion Body Myositis

Subjects
United States. Food and Drug Administration, Myositis -- Drug therapy, Shock, Business, international, Law
Abstract

Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today received Fast Track designation from the US Food and Drug Administration (FDA) [...]

Published
2019

8. ORPHAZYME RECEIVES ORPHAN DRUG DESIGNATION TO ARIMOCLOMOL FOR INCLUSION BODY MYOSITIS FROM THE U.S. FDA

Subjects
United States. Food and Drug Administration, International Business Machines Corp. -- Product development, Myositis -- Drug therapy, Orphan drugs -- Product development, Computer industry -- Product development, Microcomputer industry, Computer industry, Business, international
Abstract

(GLOBE NEWSWIRE via COMTEX) -- Orphazyme A/S Ole Maaloes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 7 November 2017 Orphazyme A/S ('Orphazyme' or the 'Company'), a Danish [...]

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results